Coronavirus API Supply Impact A ‘Big Wake Up Call’ For India
IPA President Satish Reddy Says Government And Industry Must Act Promptly
Satish Reddy, president of the Indian Pharmaceutical Alliance and chair of Dr Reddy’s Laboratories, says that the government and domestic industry have to act promptly, and in tandem, to regain India’s glory days of dominance in active pharmaceutical ingredients and avoid a public health problem.
You may also be interested in...
India has published a list of APIs and formulations for which exports will be restricted, with immediate effect. The move comes against the backdrop of growing concerns over the off-patent industry’s supply chain given the ongoing pressures caused by the coronavirus outbreak.
The two-day India Pharmaceutical Forum in Mumbai highlighted key aspects of quality management and its challenges, trends on inspection outcomes in India and emerging concerns of 'dangerous cross contamination.'
Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.